Previous 10 | Next 10 |
home / stock / iphyf / iphyf news
Innate Pharma S.A. (IPHA) First Half 2022 Financial Results and Business Update September 15, 2022 8:00 AM ET Company Participants Henry Wheeler – Investor Relations Mondher Mahjoubi – Chief Executive Officer Joyson Karakunnel – Executive Vic...
The following slide deck was published by Innate Pharma S.A. in conjunction with their 2022 Q2 earnings call. For further details see: Innate Pharma S.A. 2022 Q2 - Results - Earnings Call Presentation
France's Innate Pharma (NASDAQ:IPHA) said it will receive a $5M milestone payment from AstraZeneca (NASDAQ:AZN) as its monoclonal antibody IPH5201 will advance into a phase 2 trial in lung cancer. Innate will be responsible for conducting the study, while the two companies will...
Innate Pharma SA (IPHA) Q1 2022 Earnings Conference Call May 10, 2022 08:00 AM ET Company Participants Henry Wheeler - VP and Head of IR Mondher Mahjoubi - Chairman of Executive Board and CEO Joyson Karakunnel - Executive VP and Chief Medical Officer Yannis Morel - Executive VP of Product Por...
The following slide deck was published by Innate Pharma S.A. in conjunction with this event. For further details see: Innate Pharma (IPHA) Investor Presentation - Slideshow
Innate Pharma S.A. (IPHA) Q4 2021 Earnings Conference Call March 24, 2022 09:00 ET Company Participants Henry Wheeler - Head, Investor Relations Mondher Mahjoubi - Chairman and Chief Executive Officer Joyson Karakunnel - Executive Vice President and Chief Medical Officer Yannis Morel - Execut...
Innate Pharma S.A. (IPHA) Q3 2021 Results Earnings Conference Call November 16, 2021, 08:00 AM ET Company Participants Mondher Mahjoubi - Chairman of Executive Board and Chief Executive Officer Joyson Karakunnel - Executive Vice President and Chief Medical Officer Yannis Morel - Executive Vic...
The following slide deck was published by Innate Pharma S.A. in conjunction with their 2021 Q3 earnings call. For further details see: Innate Pharma S.A. 2021 Q3 - Results - Earnings Call Presentation
Innate Pharma S.A. (IPHYF) Q2 2021 Earnings Conference Call September 15, 2021 08:00 AM ET Company Participants Mondher Mahjoubi - Chairman of Executive Board & CEO Joyson Karakunnel - EVP & Chief Medical Officer Frédéric Lombard - SVP, Chief Financial Officer Henry Wheeler ...
The following slide deck was published by Innate Pharma S.A. in conjunction with their 2021 Q2 earnings call. For further details see: Innate Pharma S.A. 2021 Q2 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...
SAR443579/IPH6101, ANKET ® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by Sanofi in R/R AML, B-ALL and HR-MDS SAR443579/IPH6101 continues ...
In heavily pretreated patients with mycosis fungoides, treatment with lacutamab results in meaningful anti-tumor activity regardless of baseline KIR3DL2 expression level. Lacutamab was well-tolerated with a safety profile consistent with prior studies. Innate will host a virtual KOL...